Harvard Bioscience (NASDAQ:HBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Harvard Bioscience (NASDAQ:HBIO) to a buy rating in a research report sent to investors on Saturday morning.

A number of other brokerages have also recently commented on HBIO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harvard Bioscience in a research note on Wednesday, October 8th. Benchmark lowered their price target on Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating for the company in a research note on Wednesday, September 10th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $2.00.

Harvard Bioscience Trading Up 11.1%

Harvard Bioscience stock opened at $0.57 on Friday. Harvard Bioscience has a 1 year low of $0.28 and a 1 year high of $2.82. The company has a market cap of $25.56 million, a PE ratio of -0.44 and a beta of 1.52. The company’s 50-day moving average is $0.46 and its two-hundred day moving average is $0.45.

Institutional Trading of Harvard Bioscience

A number of large investors have recently bought and sold shares of the business. Bank of America Corp DE increased its stake in Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after purchasing an additional 11,948 shares in the last quarter. Williams & Novak LLC increased its stake in Harvard Bioscience by 37.0% during the 2nd quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 28,800 shares in the last quarter. Pasadena Private Wealth LLC increased its stake in Harvard Bioscience by 23.2% during the 2nd quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 45,872 shares in the last quarter. Deutsche Bank AG increased its stake in Harvard Bioscience by 221.1% during the 1st quarter. Deutsche Bank AG now owns 75,985 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 52,319 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in Harvard Bioscience by 491.9% during the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 58,785 shares in the last quarter. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.